



Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy

Guest Editor:

Dr. Hyewon Ko

Korea Research Institute of
Bioscience & Biotechnology,
Daejeon, Korea

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

Dear Colleagues,

Cancer immunotherapy has emerged as a pioneering treatment modality that controls the host immune system to eradicate cancer cells. However, major challenges are still present, such as limited therapeutic benefits and off-target toxicities. As in conventional cancer therapy, recently, nanomedicines have been applied as a representative drug delivery platform for cancer immunotherapy to improve therapeutic efficacy and reduce side effects. For enhanced immunotherapy, nanomedicines can be utilized to remodel the tumor microenvironments, increase antigen presentation, and stimulate the immune cells. Of various nanomedicines, polymer-based nanomedicines hold great potential in biocompatibility, feasibility for chemical modifications, and versatility in combination with other organic/inorganic materials.

This Special Issue of *Pharmaceutics* aims to cover the advanced strategies exploiting Polymeric Nanomedicines for Cancer Immunotherapy.

Dr. Hyewon Ko
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma